tbuckley/cabot-search huggingface dataset:
Immunization Against Influenza
Authors: E. J. H.
Journal: Annals of Internal Medicine (1967)

Editorial Notes1 September 1967Immunization Against InfluenzaE. J. H.E. J. H.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-67-3-677 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAn unusual number of cases of A2 influenza are expected to appear during the 1967 to 1968 season, particularly in the eastern United States. Immunization is recommended by the U. S. Public Health Service for chronically ill patients (those with cardiovascular, pulmonary, renal, and metabolic disorders, including Addison's disease and diabetes mellitus), patients in institutions (nursing homes, chronic disease hospitals), and persons over age 45.Immunization should begin as soon as possible after October 1for persons not vaccinated since July 1963 and be completed by early December. These persons should receive an initial dose of bivalent vaccine (adults and... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1967Volume 67, Issue 3_Part_1Page: 677-677KeywordsCardiovascular diseasesChronic kidney diseaseDiabetes mellitusMedical servicesMetabolic disordersNursing homesPulmonary diseasesVaccines ePublished: 1 December 2008 Issue Published: 1 September 1967 PDF downloadLoading ...
Increased risk of multiple myeloma in primary Sjögren’s syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies
Authors: Johannes Mofors, Albin Björk, Karin E Smedby, Marika Kvarnström, Helena Forsblad-d'Elia, Sara Magnusson-Bucher, Per Eriksson, Thomas Mandl, Eva Baecklund, Gunnel Nordmark, Marie Wahren-Herlenius
Journal: Annals of the Rheumatic Diseases (2019)

Primary Sjogren’s syndrome is a systemic autoimmune disease characterised by chronic inflammation of exocrine glands, primarily the salivary and lacrimal glands. In the glands, ectopic lymphoid tissue may form, with germinal centre-like structures promoting B-cell DNA rearrangements and Ro/SSA and La/SSB autoantibody production.1 The presence of autoantibodies correlate with disease severity and influence long-term outcome.2 High circulating levels of BAFF also contributes to the polyclonal B-cell activation, and increased plasmablast differentiation and hypergammaglobulinaemia are common.3 4 The autoantibodies can induce production of type I interferons, which further a positive feed-forward loop of chronic B-cell activation.3

Patients with primary Sjogren’s syndrome have a 5–15 times higher risk of lymphoma than the general population, corresponding to a lifetime risk of 5%–10%.5 The malignancies are commonly B-cell non-Hodgkin lymphomas, predominantly marginal zone lymphomas. However, whether there is an increased risk of multiple myeloma in Sjogren’s syndrome has not been unequivocally defined (see online supplementary text).6 Considering the abundance and activity of …
Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index
Authors: Nelli Bejanyan, Mei-Jie Zhang, Khalid Bo-Subait, Hai-Lin Wang, Erica D. Warlick, Claudio G Brunstein, Brenda M Sandmaier, Mark Litzow, Partow Kebriaei, Wael Saber, Daniel J. Weisdorf
Journal: Blood (2019)
Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma
Authors: Ehsan Tabari, Alexander F Lovejoy, Hai Lin, Christopher R Bolen, Seng Lor Saelee, Joshua P Lefkowitz, David M. Kurtz, Patrik Vitazka, Jeffrey M. Venstrom, Tina G Nielsen, Joana M Parreira, Daniel M Klass, Khai T Luong
Journal: Blood (2019)
Heterogeneity Between Genetic Variants as a Proxy for Pleiotropy in Mendelian Randomization
Authors: Dipender Gill
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Authors: René Rodriguez-Gutierrez, José Gerardo Gonzalez-Gonzalez, Jorge A Zuñiga-Hernandez, Rozalina G McCoy
Journal: BMJ (2019)

ABSTRACT Diabetes is a major and costly health concern worldwide, with high morbidity, disability, mortality, and impaired quality of life. The vast majority of people living with diabetes have type 2 diabetes. Historically, the main strategy to reduce complications of type 2 diabetes has been intensive glycemic control. However, the body of evidence shows no meaningful benefit of intensive (compared with moderate) glycemic control for microvascular and macrovascular outcomes important to patients, with the exception of reduced rates of non-fatal myocardial infarction. Intensive glycemic control does, however, increase the risk of severe hypoglycemia and incurs additional burden by way of polypharmacy, side effects, and cost. Additionally, data from cardiovascular outcomes trials showed that cardiovascular, kidney, and mortality outcomes may be improved with use of specific classes of glucose lowering drugs largely independently of their glycemic effects. Therefore, delivering evidence based, patient centered care to people with type 2 diabetes requires a paradigm shift and departure from the predominantly glucocentric view of diabetes management. Instead of prioritizing intensive glycemic control, the focus needs to be on ensuring access to adequate diabetes care, aligning glycemic targets to patients’ goals and situations, minimizing short term and long term complications, reducing the burden of treatment, and improving quality of life.
Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?
Authors: Jan-Willem C. Alffenaar, Onno W. Akkerman, Simon Tiberi, Giovanni Sotgiu, Giovanni Battista Migliori
Journal: European Respiratory Journal (2019)

<b>Factors known to have an impact on bedaquiline exposure are present in patients with M/XDR-TB. As we have seen with fluoroquinolones the impact of variable drug exposure needs to be studied to understand the impact on treatment outcome.</b>http://bit.ly/2JMlJJF
QOLP-40. END-OF-LIFE CARE FOR GLIOBLASTOMA PATIENTS IN JAPAN
Authors: Tomoko Omura, Yasuji Miyakita, Makoto Ohno, Masamichi Takahashi, Kenji Fujimoto, Takaki Omura, Hitomi Sato, Yoshitaka Narita
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Despite aggressive treatment with surgery and chemo-radiation therapy, it is difficult to cure patients with glioblastoma (GBM). The end-of-life (EOL) phase of patients with GBM, and related problems, have not yet been adequately studied. Unlike in other countries, most cancer patients died in the hospital (84%) in 2017, but the Japanese government has recommended palliative home care and the number of deaths at home has recently been increasing. This study explores the current situation of EOL care for GBM patients in Japan. METHODS We retrospectively examined the clinical course and EOL phase of 166 consecutive patients who were treated in our hospital between 2010 and 2017. RESULT: In total, 107 patients died; 27 (25.7%) at home, 24 (22.8%) in hospice care, 8 (7.6%) in nursing homes, 46 (43.9%) in hospitals (long-term care hospitals [LTCH; 19.8%], our hospital [13.3%], and other neurosurgical hospitals [10.4%]). According to our previous research, in 2001–2005, 6% of GBM patients died at home, 3% in hospice case, and 91% in the hospital. The KPSof patients who started palliative home care or transferred to another hospital was 50–60. The median survival time and length of EOL phase for patients who died at home were 498 and 76.5 days; 395 and 103 days in hospice care; 533 days and 149 days in LTCH; 374 days and 52 days in our hospital; 338 and 75.5 days in other neurosurgical hospital; and 557 days and 37 days in nursing homes, respectively. CONCLUSION The number of GBM patients who died at home in Japan is increasing, and we must consider the problems of the EOL phase and improve the quality of EOL care.
RARE-52. AN EXTRA-VENTRICULAR NEUROCYTOMA PRESENTING WITH DIFFUSE LEPTOMENINGEAL DISEASE WITH OPTIC NEURITIS, A CASE REPORT
Authors: Carlos Eduardo Silva Correia, Ruham Alshiekh Nasany
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Neurocytoma is classically a rare intraventricular tumor that affects young adults. Due to its location, it usually presents with obstructive hydrocephalus and typically has a favorable prognosis after adequate surgical intervention. CASE: In this report, we describe the case of a 19-year-old man who developed progressive decreased visual acuity and headaches that led to a diagnosed of hydrocephalus and a ventriculoperitoneal shunt (VPS) placement. Work up at presentation revealed a thoracic spinal cord tumor which was completed resected and pathology was consistent with extra-ventricular neurocytoma. With no further intervention, he experienced signs of worsening intracranial pressure (ICP) and visual acuity, becoming steroid-dependent. Repeat imaging 3 months later showed early signs of leptomeningeal disease (LMD), optic nerve enhancement, and diffuse dural thickening. A dural biopsy was done and read as nonspecific inflammation. He then came to our center for a second opinion. We reviewed pathology from original tumor and confirmed extra-ventricular neurocytoma. We, however, read the dural biopsy as an organizing subdural hematoma. We analyzed his cerebrospinal fluid (CSF) and cytology showed neurocytoma cells, linking his LMD to initial diagnosis. He went on to receive photon craniospinal radiation (CSI) with clinical improvement and decreased steroid requirements. Most recent imaging showed improving LMD. DISCUSSION Extra-ventricular neurocytoma is an extremely rare disease with very few cases reported in the literature and our case is unique due to the severe leptomeningeal involvement affecting the optic nerves and the presence of neurocytoma cells on the CSF. There is no consensus on how to best treat these cases, however, our patient improved after CSI.
Physiotherapy for Bell's Palsy
Authors: J. Shulman
Journal: BMJ (1958)

<b>Aims:</b> To examine the mortality experience of 4221 employees from 1973 to 1999 and the illness absence patterns for 2203 employees from 1990 to 1999 of a chemical and refinery facility in Louisiana. <b>Methods:</b> Mortality and illness absence data were extracted from the Shell Oil Company’s health surveillance system (HSS). The standardised mortality ratio was used as a measure of mortality risk. Morbidity frequency and duration of absence were calculated by age, sex, and four health risk factors (cigarette smoking, high blood pressure, hypercholesterolaemia, and obesity). <b>Results:</b> Male employees experienced a significant deficit in mortality for all causes of death, all cancers, lung cancer, heart disease, and respiratory disease compared with the corresponding US population. Brain cancer was non-significantly increased, with six observed and five expected deaths; mortality from leukaemia was consistently lower than expected. The majority of employees had no illness absences of six days or longer during the 10 year study period. The loss of productivity (in terms of days of absence) was greater for employees with health risk factors. Ever smoking male employees had a 79% increase of heart disease and more than 50% higher rates of respiratory disease and musculoskeletal disorders compared to non-smokers. Smokers were absent 2.9 and 1.6 more days than non-smokers and ex-smokers, respectively. <b>Conclusions:</b> Regardless of the comparison population, significantly fewer deaths were seen for all causes combined, all cancers, lung cancer, heart disease, or non-malignant respiratory disease. Illness absence rates and duration were higher among employees with health risk factors.
Notch1-Activated B Cells Have an Immunomodulatory Function Enhancing Th2 and Treg Immune Response Via IL-33-ST2 Pathway
Authors: Hiroshi Arima, Momoko Nishikori, Yasuyuki Otsuka, Kiyotaka Izumi, Wataru Kishimoto, Akifumi Takaori-Kondo
Journal: Blood (2016)
Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide
Authors: Sinto Chirackal, Esteban Braggio, Rahman Atiqur, Gregory J Ahmann, Yuan Xiao Zhu, A. Keith Stewart, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca
Journal: Blood (2019)
System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival
Authors: Astrid Tschan-Plessl, Eivind Heggernes Ask, Thea Johanne Gjerdingen, Michelle Saetersmoen, Hanna Julie Hoel, Merete Thune Wiiger, Johanna Olweus, Björn E Wahlin, Amir Horowitz, Todd A Fehniger, Harald Holte, Arne Kolstad, Karl-Johan Malmberg
Journal: Blood (2019)
Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study
Authors: Hui-qiang Huang, Won-Seog Kim, Ming Yao, Tae Min Kim, DocHyun Yoon, Seok-Goo Cho, Hyeon-Seok Eom, Su-Peng Yeh, Soon Thye Lim, Yuqin Song, Shizhou Liu, Grace Gao, Lijia Zhang, Min Qing, Ming Qi, Jin Seok Kim, Yok Lam Kwong, Jie Jin, Yuankai Shi, Jun Zhu
Journal: Blood (2019)
Pharmacologic inducers of the uric acid exporter ABCG2 as potential drugs for treatment of gouty arthritis
Authors: Bojana Ristic, Mohd Omar Faruk Sikder, Yangzom D. Bhutia, Vadivel Ganapathy
Journal: Asian Journal of Pharmaceutical Sciences (2019)

Uric acid is the end product of purine catabolism and its plasma levels are maintained below its maximum solubility in water (6–7 mg/dl). The plasma levels are tightly regulated as the balance between the rate of production and the rate of excretion, the latter occurring in urine (kidney), bile (liver) and feces (intestinal tract). Reabsorption in kidney is also an important component of this process. Both excretion and reabsorption are mediated by specific transporters. Disruption of the balance between production and excretion leads to hyperuricemia, which increases the risk of uric acid crystallization as monosodium urate with subsequent deposition of the crystals in joints causing gouty arthritis. Loss-of-function mutations in the transporters that mediate uric acid excretion are associated with gout. The ATP-Binding Cassette exporter ABCG2 is important in uric acid excretion at all three sites: kidney (urine), liver (bile), and intestine (feces). Mutations in this transporter cause gout and these mutations occur at significant prevalence in general population. However, mutations that are most prevalent result only in partial loss of transport function. Therefore, if the expression of these partially defective transporters could be induced, the increased number of the transporter molecules would compensate for the mutation-associated decrease in transport function and hence increase uric acid excretion. As such, pharmacologic agents with ability to induce the expression of ABCG2 represent potentially a novel class of drugs for treatment of gouty arthritis.
The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
Authors: Laura A Evans, Ronald S. Go, Bharat Nandakumar, Francis K. Buadi, Angela Dispenzieri, David Dingli, Martha Q. Lacy, Suzanne R. Hayman, Prashant Kapoor, Nelson Leung, Amie Fonder, Miriam A. Hobbs, Yi L. Hwa, Eli Muchtar, Rahma M Warsame, Taxiarchis Kourelis, Stephen J Russell, John A. Lust, Mustaqeem Siddiqui, Robert A. Kyle, Morie A Gertz, S. Vincent Rajkumar, Shaji K. Kumar, Wilson I Gonsalves
Journal: Blood (2019)
Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial
Authors: Catherine Diefenbach, Brad S. Kahl, Lalita Banerjee, Andrew K McMillan, Fiona Miall, Javier Briones, Raul Cordoba, Jamie Hirata, YiMeng Chang, Lisa Musick, Pau Abrisqueta
Journal: Blood (2019)
Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility
Authors: Anna L Brown, Milena Babic, Andreas Schreiber, Jinghua Feng, Julia Dobbins, Peer Arts, Paul Wang, Kerry Phillips, Devendra K Hiwase, Parvathy Venugopal, Susan Branford, Nicola Poplawski, Christopher N Hahn, Hamish S Scott
Journal: Blood (2019)
The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone
Authors: Jiri Minarik, Alexandra Jungova, Jan Straub, Evzen Gregora, Jana Bryknarova, Blanka Nemcova, Roman Hajek
Journal: Blood (2019)
Targeting CXCR4, VLA4, and CXCR2 for Hematopoietic Stem Cell Mobilization
Authors: Daniel Cancilla, Haresh Thakellapalli, Marvin J Meyers, Michael P. Rettig, Ezhilarasi Chendamarai, Stephanie Christ, Darja Karpova, Peter G Ruminski, Julie K. Ritchey, Dwight M. Morrow, Michael Prinsen, John F. DiPersio
Journal: Blood (2019)
Single Cell Analysis of Circulating Endothelial Cells in Allogeneic Hematopoietic Stem Cell Transplant; To Whom Do They Belong: Host or Donor?
Authors: Camillo Almici, Francesca Fontana, Giovanna Piovani, Piera Balzarini, Arabella Neva, Benedetto Bruno, Cristina Skert, GianLuca Rotta, Simona Fisogni, Rosanna Verardi, Andrea Bianchetti, Simona Braga, Michele Malagola, Nicolò Manaresi, Fabio Facchetti, Mirella Marini, Domenico Russo
Journal: Blood (2019)
NIMG-25. LESION-NETWORK ANALYSIS TO IDENTIFY PREFERENTIALLY-ENGAGED NETWORKS IN EPILEPTOGENIC TUMORS
Authors: Alireza Mansouri, Alexandre Boutet, Gavin Elias, Jurgen Germann, Karim Mithani, George Ibrahim, Andres Lozano, Taufik Valiante
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Lesion network mapping (LNM) is a method used to identify potential networks that can be ascribed to particular neurological functions/ deficits. LNM has yet to be implemented for large brain lesions such as tumors. OBJECTIVES: To apply LNM for potential identification of vulnerable epileptogenic networks in tumors causing medically-refractory epilepsy (MRE), compared with non-epileptogenic tumors. METHODS MRE and non-epileptogenic lesions were normalized to standard space for group analysis. These were used as a seed in high-resolution normative resting state fMRI, which was then transformed to t-maps and thresholded by t = 5.1; this corrected for multiple comparisons (Bonferroni corrections) across the whole brain at pcor &lt; 0.05. The statistically-significant thresholded maps were binarized and summed connectivity maps were generated for both groups. This allowed computation of voxel-wise odds ratios (VORs) in order to identify voxels that were more likely associated with tumors that either did or did not result in MRE. RESULTS Twenty-seven patients were included. Eleven brain metastases with no history of seizures, M/F: 5/6, mean age 68.4+/-8.4 years, and 16 had MRE (10 low-grade glioma, 2 cavernoma, 3 “other”), M/F: 7:9, mean age 33.7 +/-12.2 years. Lesions causing MRE were preferentially located in the cingulate gyrus, calcarine fissure, parahippocampal gyrus and lateral temporal neocortex. The resting-state networks that were &gt;1.5x likely to be connected with MRE lesions were the salience, executive control, and dorsal default mode networks. CONCLUSION In this proof of concept study, we have demonstrated that (1) in addition to stroke, tumors may also be amenable to LNM and (2) the underlying normative neural circuitry may in part explain the propensity of particular lesions toward development of MRE. This has ramifications in patient counseling and surgical management planning, as earlier surgery could be applied for lesions thought to be more prone to development of MRE.
Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma
Authors: Meena Bansal, David S. Siegel, Jaeil Ahn, Rena Feinman, David H. Vesole, Joshua R Richter, Andrew L. Pecora, Elli Gourna Paleoudis, Scott D. Rowley, Michele L. Donato, Robert Korngold, Palka Anand, Laura McBride, Kristin Ivanovski, Noa Biran
Journal: Blood (2019)
Abstract 13093: Height as a Causal Risk Factor for Atrial Fibrillation: A Mendelian Randomization Study
Authors: Michael Levin, Renae Judy, Daniel Rader, Benjamin F Voight, Scott M Damrauer
Journal: Circulation (2019)

Introduction: Observational studies have identified an association between increasing height and risk of atrial fibrillation (AF), although the mechanism and causal nature of this relationship have...
Variable Response to BCL2 Inhibition in MDS Is Enhanced across MDS Subtypes with Synergistic Combination of BCL2+MCL1 Inhibition
Authors: Melissa A. Fischer, Maria Arrate, Merrida A Childress, Brianna N Smith, Yuanbin Song, Rana Gbyli, Thomas Stricker, Stephanie Halene, Michael R. Savona
Journal: Blood (2019)